The U.S. Food and Drug Administration has granted approval for application ANDA077697 submitted by Apotex Inc. The approval covers a generic ophthalmic solution of latanoprost (0.005%). The product is listed as discontinued in marketing status. The original submission received approval on March 22, 2011. Subsequent supplemental submissions for labeling were approved on November 28, 2012, and December 17, 2015.
규제 업데이트2026년 9월 5일•1분 읽기
FDA Approves Apotex Latanoprost Ophthalmic Solution (ANDA077697)
The FDA approved Apotex's ANDA077697 for a generic latanoprost ophthalmic solution, with labeling supplements approved in 2012 and 2015.
PharmaCountry 팀이 정리했습니다 · 출처: FDA.gov
평점
(0)
(0)
(0)
(0)
(0)
평가 남기기